KR960705843A - 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases) - Google Patents

펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)

Info

Publication number
KR960705843A
KR960705843A KR1019960702437A KR19960702437A KR960705843A KR 960705843 A KR960705843 A KR 960705843A KR 1019960702437 A KR1019960702437 A KR 1019960702437A KR 19960702437 A KR19960702437 A KR 19960702437A KR 960705843 A KR960705843 A KR 960705843A
Authority
KR
South Korea
Prior art keywords
alkyl
methylamide
phenylalanine
leusil
aryl
Prior art date
Application number
KR1019960702437A
Other languages
English (en)
Inventor
존 몬타나
존나단 디킨즈
데이비드 알렌 오웬
앤드류 더글러스 박스터
Original Assignee
앤드류 리차드
키로사이언스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 앤드류 리차드, 키로사이언스 리미티드 filed Critical 앤드류 리차드
Publication of KR960705843A publication Critical patent/KR960705843A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 하기의 식(Ⅰ)의 화합물로서,
여기서 R1은 C1-6알킬, C2-6알케닐, 아릴, (C1-6알킬)아릴 또는 C1-6알킬-AR9이고, A는 O, NR9이고, 또는 S(O)m이고, m은 0 내지 2이고, R9은 H, C1-4알킬, 아릴 또는 (C1-4알킬)아릴; R2는 H 또는 C1-6알킬; R4는 H 또는 아미노(NH2), 아릴 아미노, 보호된 아미노, 아릴, 디(C1-6알킬)아미노, 모노(C1-6알킬)아미노, CO2H, 보호된 카르복실, 카르바모일, 모노(C1-6알킬)카르바모일 또는 디(C1-6알킬)카르바모일에 의해 선택적으로 치환된 C1-6알킬, 및 R5는 H 또는 C1-6알킬, 또는 NR4R5은 피롤리디노, 피페리디도 또는 모르포리노; R6는 선택적으로 치환된 C3-6시클로알킬, C3-6시클로알케닐, C1-6알킬, 벤질, (C1-6알콕시)벤질, 벤질옥시벤질 또는 3-인돌리메틸; Alk는 C1-6알킬 또는 C2-6알케닐 및 n=0 또는 1; R7은 H 또는 R10CO, 여기서 R10은 C1-4알킬, (C1-4알킬)아릴, C3-6시클로알킬, (C3-6시클로알킬) C1-4알킬, C2-6알케닐 또는 (C2-6알케닐)아릴; 및 R8은 H, C1-4알킬, (C1-4알킬)아릴 또는 아릴; 또는 그들의 염, 솔베이트 또는 수화물이다.
이런 화합물들은 메타로프로테인아제, TNF 및/또는 다른 활성도와 관련된 상태를 처리하는데 사용될 수 있다.

Description

펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEINASES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식(Ⅰ)의 화합물, 또는 그들의 염, 솔베이트 또는 수화물.
    여기서 R1은 C1-6알킬, C2-6알케닐, 아릴, (C1-6알킬)아릴 또는 C1-6알킬-AR9이고, A는 O, NR9이고, 또는 S(O)m이고, m은 0 내지 2이고, R9은 H, C1-4알킬, 아릴 또는 (C1-4알킬)아릴; R2는 H 또는 C1-6알킬; R4는 H 또는 아미노(NH2), 아릴 아미노, 보호된 아미노, 아릴, 디(C1-6알킬)아미노, 모노(C1-6알킬)아미노, CO2H, 보호된 카르복실, 카르바모일, 모노(C1-6알킬)카르바모일 또는 디(C1-6알킬)카르바모일에 의해 선택적으로 치환된 C1-6알킬, 및 R5는 H 또는 C1-6알킬, 또는 NR4R5은 피롤리디노, 피페리디노 또는 모르포리노; R6는 선택적으로 치환된 C3-6시클로알킬, C3-6시클로알케닐, C1-6알킬, 벤질, (C1-6알콕시)벤질, 벤질옥시벤질 또는 3-인돌리메틸, Alk는 C1-6알킬 또는 C2-6알케닐 및 n=0 또는 1; R7은 H 또는 R10CO, 여기서 R10은 C1-4알킬, (C1-4알킬)아릴, C3-6시클로알킬, (C3-6시클로알킬)C1-4알킬, C2-6알케닐 또는 (C2-6알케닐)아릴; 및 R8은 H, C1-4알킬, (C1-4알킬)아릴 또는 아릴이다; 또는 그들의 염, 솔베이트 또는 수화물.
  2. 제1항에 있어서, R1은 알킬, 알케닐, 아릴, 알킬아릴이고, R7및 R8은 각각 H인 화합물.
  3. 제1항에 있어서, 화합물은 N-〔N-(메르캅토아세틸)-L-레우실〕-L-페닐알라닌 메틸아미드, N-〔(아세토메르캅토아실)-L-레우실〕-L-페닐알라닌 메틸아미드, (RS)
    -2-(아세틸티오)펜타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-3-메틸부타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-2-페닐아세틸
    -L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-3-페닐프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-(아세틸티오)-4-페닐부타노일-L-레우실
    -L-페닐알라닌 N-메틸아미드, N-(아세틸메르캅토아실)-L-트레오닐-L-페닐알라닌 메틸아미드, N-(아세틸메르캅토아실)-L-트레오닐-L-레우실-L-트립토판 메틸아미드, (RS)-2-메르캅토펜타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-3-메틸부타노일-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-2-페닐아세틸-L-레우실-L-페닐알라닌 N-메틸아미드, (RS)-2-메르캅토-3-페닐프로파노일-L-레우실-L-페닐알라닌 N-메틸아미드, N-〔N-(메르캅토아세틸)-L-트레오닐〕-L-페닐알라닌 메틸아미드 및 N-〔N-(메르캅토아세틸)-L-레우실〕-L-트립토판 메틸아미드로부터 선택된 화합물.
  4. 제1항 내지 제3항 중 어느 하나의 항의 화합물과 생리학적으로 허용가능한 희석액 또는 담체로 이루어지는 치료에 사용하기 위한 제약학적 조성물.
  5. 매트릭스 메탈로프로테인아제 또는 TNF 활성과 관련된 상태의 억제 또는 치료를 위한 약제의 제조를 위한 제1항 내지 제3항 중 어느 하나의 항의 화합물의 용도.
  6. 제5항에 있어서, 상기 상태는 염증, 발열, 심장맥관의 효과, 출혈, 응고 및 급성상태 반응, 악태증 및 식욕결핍, 급성 간염, 쇼크 상태, 조직이식 대 숙주 반응, 자가면역 질병, 말라리아, 리퍼퓨션(reperfusion)질병, 수막염, 건선, 류마토이드 관절염, 다중 경화증 및 종양들로부터 선택되는 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702437A 1993-11-10 1994-11-10 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases) KR960705843A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939323165A GB9323165D0 (en) 1993-11-10 1993-11-10 Compounds
GB9323165.2 1993-11-10
PCT/GB1994/002471 WO1995013289A1 (en) 1993-11-10 1994-11-10 Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases

Publications (1)

Publication Number Publication Date
KR960705843A true KR960705843A (ko) 1996-11-08

Family

ID=10744943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702437A KR960705843A (ko) 1993-11-10 1994-11-10 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)

Country Status (22)

Country Link
US (1) US5853623A (ko)
EP (1) EP0728144B1 (ko)
JP (1) JPH09505041A (ko)
KR (1) KR960705843A (ko)
CN (1) CN1134705A (ko)
AT (1) ATE188969T1 (ko)
AU (1) AU679286B2 (ko)
BR (1) BR9408025A (ko)
CA (1) CA2173470A1 (ko)
CZ (1) CZ287780B6 (ko)
DE (1) DE69422726T2 (ko)
DK (1) DK0728144T3 (ko)
ES (1) ES2143611T3 (ko)
FI (1) FI961976A0 (ko)
GB (1) GB9323165D0 (ko)
GR (1) GR3033103T3 (ko)
HK (1) HK1015139A1 (ko)
HU (1) HU217344B1 (ko)
NO (1) NO961888D0 (ko)
PL (1) PL180403B1 (ko)
PT (1) PT728144E (ko)
WO (1) WO1995013289A1 (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ271893A (en) * 1993-08-23 1997-11-24 Immunex Corp Inhibitors of tnf-alpha secretion
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
CN1193978A (zh) * 1994-10-05 1998-09-23 奇罗斯恩有限公司 肽基化合物和它们作为金属蛋白酶抑制剂的医疗用途
AU701279B2 (en) * 1995-05-10 1999-01-21 Darwin Discovery Limited Peptide compounds which inhibit metalloproteinase and TNF liberation and their therapeutic uses
EP0824543A1 (en) * 1995-05-10 1998-02-25 Chiroscience Limited Peptide compounds which inhibit metalloproteinase and tnf liberation, and their therapeutic use
DE69627483T2 (de) * 1995-05-10 2004-04-01 Darwin Discovery Ltd., Slough Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
US5677282A (en) * 1995-06-07 1997-10-14 Proscript, Inc. Amino acid amides of 1,3,4-thiadiazoles as matrix metalloproteinase
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
GB2318353B (en) * 1995-07-20 1999-10-06 British Biotech Pharm Metalloproteinase inhibitors
JP2008024720A (ja) * 1995-07-26 2008-02-07 Mitsubishi Chemicals Corp ペニシラミンアミド誘導体
ES2186803T3 (es) * 1995-10-05 2003-05-16 Darwin Discovery Ltd Peptidos tio-sustituidos como inhibidores de metaloproteinasas y de la liberacion de tnf.
AU7139996A (en) * 1995-10-05 1997-04-28 Chiroscience Limited Mercaptoamide derivatives and their therapeutic use
GB9523066D0 (en) * 1995-11-10 1996-01-10 Chiroscience Ltd Compounds and their therapeutic use
DE69620639T2 (de) * 1995-11-22 2002-10-17 Darwin Discovery Ltd., Cambridge Mercaptoalkylpeptidylverbindungen mit einem imidazolsubstituenten und ihre verwendung als inhibitoren der matrix metalloproteinasen (mmp) und/oder des tumor necrosis faktors (tnf)
CZ298814B6 (cs) 1996-01-23 2008-02-13 Shionogi & Co., Ltd. Sulfonované deriváty aminokyselin a metaloproteasové inhibitory obsahující tyto deriváty
US6919375B1 (en) 1996-01-23 2005-07-19 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
GB9607249D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607119D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
WO1997037658A1 (en) * 1996-04-04 1997-10-16 F.Hoffmann-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US5852213A (en) * 1996-07-10 1998-12-22 American Cyanamid Company Mercaptoketones and mercaptoalcohols and a process for their preparation
AU714687B2 (en) * 1996-07-22 2000-01-06 Monsanto Company Thiol sulfone metalloprotease inhibitors
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US6953788B1 (en) 1996-09-19 2005-10-11 Aventis Pharmaceuticals Inc. 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
GB9624817D0 (en) * 1996-11-28 1997-01-15 British Biotech Pharm Metalloproteinase inhibitors
ATE258063T1 (de) * 1997-03-03 2004-02-15 Darwin Discovery Ltd Selektive mmp inhibitoren mit verringerten nebenwirkungen
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
KR20000075955A (ko) 1997-03-04 2000-12-26 죤 에이치. 뷰센 방향족 술포닐 알파-히드록시 히드록삼산 화합물
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6638952B1 (en) 1997-03-04 2003-10-28 Pharmacia Corporation Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US6034136A (en) 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors
WO1999007679A1 (en) * 1997-08-08 1999-02-18 Chiroscience Limited Peptidyl compounds having mmp and tnf inhibitory activity
PL341379A1 (en) 1997-11-14 2001-04-09 Searle & Co Aromatic sulphone substituted hydroxamic acid as inhibitor of metalloprotease
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
AU1836800A (en) * 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. Amidomalonamides and their use as inhibitors of matrix metalloproteinase
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
JP2003521476A (ja) * 1999-06-15 2003-07-15 メルク エンド カムパニー インコーポレーテッド チオール誘導体、メタロ−β−ラクタマーゼ阻害剤
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
IL151125A0 (en) 2000-03-21 2003-04-10 Procter & Gamble Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
PL357275A1 (en) * 2000-03-21 2004-07-26 The Procter & Gamble Company Carbocyclic side chain containing metalloprotease inhibitors
CA2401728A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
FR2823212B1 (fr) * 2001-04-10 2005-12-02 Inst Nat Sante Rech Med Inhibiteurs de la toxine botulique de type b
AP2003002908A0 (en) 2001-05-11 2003-12-31 Pharmacia Corp Aromatic sulfone hydroxamates and their use as protease inhibitors
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
ES2342378T3 (es) * 2002-08-20 2010-07-06 Astellas Pharma Inc. Inhibidor de degradacion de matriz extracelular del cartilago artrodial.
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7570250B2 (en) * 2006-05-04 2009-08-04 Yi-Ming Tseng Control device including a ball that stores data
DE202010018378U1 (de) 2009-04-10 2016-04-07 Tufts Medical Center, Inc. PAR-1-Aktivierung durch Metalloproteinase-1 (MMP-1)
CA3026074A1 (en) 2016-06-01 2017-12-07 M3 Biotechnology, Inc. N-hexanoic-l-tyrosine-l-isoleucine-(6)-aminohexanoic amide compounds and their use to treat neurodegenerative diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3774858D1 (de) * 1986-12-24 1992-01-09 Beecham Group Plc Derivate von n-(2-alkyl-3-mercaptoglutaryl)-alpha-aminosaeuren und deren verwendung als collagenase-inhibitoren.
JP2586942B2 (ja) * 1987-03-17 1997-03-05 リサーチ コーポレーシヨン テクノロジーズ インコーポレーテツド 哺乳動物コラゲナーゼの合成阻止剤
US5144043A (en) * 1988-06-15 1992-09-01 Centocor Cleavable bifunctional coupling agents
AU5292193A (en) * 1992-10-02 1994-04-26 Merck & Co., Inc. N-(mercaptoacyl)peptidyl derivatives as antidegenerative agents

Also Published As

Publication number Publication date
CA2173470A1 (en) 1995-05-18
EP0728144B1 (en) 2000-01-19
HK1015139A1 (en) 1999-10-08
US5853623A (en) 1998-12-29
HU217344B1 (hu) 2002-02-28
CN1134705A (zh) 1996-10-30
NO961888L (no) 1996-05-09
GR3033103T3 (en) 2000-08-31
FI961976A (fi) 1996-05-09
CZ134996A3 (en) 1996-10-16
GB9323165D0 (en) 1994-01-05
HU9601244D0 (en) 1996-07-29
ATE188969T1 (de) 2000-02-15
PL314300A1 (en) 1996-09-02
HUT73799A (en) 1996-09-30
DE69422726D1 (de) 2000-02-24
WO1995013289A1 (en) 1995-05-18
DE69422726T2 (de) 2000-06-08
PT728144E (pt) 2000-07-31
AU8113394A (en) 1995-05-29
NO961888D0 (no) 1996-05-09
PL180403B1 (pl) 2001-01-31
DK0728144T3 (da) 2000-07-03
BR9408025A (pt) 1996-12-17
AU679286B2 (en) 1997-06-26
ES2143611T3 (es) 2000-05-16
FI961976A0 (fi) 1996-05-09
EP0728144A1 (en) 1996-08-28
JPH09505041A (ja) 1997-05-20
CZ287780B6 (en) 2001-02-14

Similar Documents

Publication Publication Date Title
KR960705843A (ko) 펩티딜 화합물과 메탈로프로테인아제의 억제제로서 그들의 치료학적 용도(peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases)
WO1995013289B1 (en) Peptidyl compounds and their therapeutic use as inhibitors of metalloproteinases
UA39093C2 (uk) Похідні пептидів, що є інгібіторами еластази лейкоцитів людини, спосіб їх отримання та фармацевтична композиція
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
KR960703580A (ko) 눈의 염증성 질환을 치료하기 위한 3-벤조일페닐아세트산 유도체를 함유하는 국소투여가능한 조성물(Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders)
BR0014254A (pt) Nova classe de agentes de citodiferenciação e inibidores de desacetilase de histona, e métodos de uso dos mesmos
TW345575B (en) Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
BRPI0409417A (pt) método para usar um composto, composto, e, composição
RU95110938A (ru) Производные 1-(2-оксоацетил)пиперидин-2-карбоновых кислот, фармацевтическая композиция, способ лечения, способ получения
JPH11507045A (ja) 可逆性システインプロテアーゼ抑制剤
HUP0202381A2 (hu) MEK-inhibitor hatású fenil-amino-benzoesav-származékok alkalmazása krónikus fájdalom kezelésére szolgáló gyógyszerkészítmények előállítására
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
MX9802680A (es) Peptidos substituidos como inhibidores para metaloproteinasas y liberacion de tnf.
RU95112456A (ru) Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения
EA199900057A1 (ru) Ингибиторы матриксных металлопротеиназ
KR950016727A (ko) 트롬보모듈린 발현을 증가시키는 방법
DE3852935D1 (de) Substituierte Alpha-Aminosäuren mit pharmazeutischer Aktivität.
BR9910678A (pt) Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
KR970707140A (ko) 평활근 세포 증식 억제제(Smooth muscle cell proliferation inhibitors)
Grdina et al. Effects of thiols on topoisomerase‐IIα activity and cell cycle progression
HUP0003475A2 (hu) Neutrofil-elasztáz gátló hatású pirrolo-pirrolon-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B701 Decision to grant
NORF Unpaid initial registration fee